UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

|X|   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

                  For the quarterly period ended June 30, 2004

                                       OR

|_|   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

     For the transition period from _________________ to __________________

                        Commission file number: 000-27582

                                  SPEEDUS CORP.
             (Exact name of registrant as specified in its charter)

             Delaware                                  13-3853788
 (State or other jurisdiction of           (I.R.S. Employer Identification No.)
  incorporation or organization)

           140 58th Street, Suite 7E
               Brooklyn, New York                          11220
     (Address of principal executive offices)            (Zip Code)

                                  718-567-4300
              (Registrant's telephone number, including area code)

                                 Not Applicable
         (Former name, former address and former fiscal year, if changed
                               since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes |X| No | |

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). Yes |_| No |X|

The number of outstanding shares of the registrant's common stock, par value
$.01 per share, as of August 14, 2004 was 16,220,325.

<PAGE>

                                  SPEEDUS CORP.
                               INDEX TO FORM 10-Q

<TABLE>
<CAPTION>
                                                                                       Page
                                                                                       ----
<S>                                                                                    <C>
PART I -- FINANCIAL INFORMATION

ITEM 1 -- Financial Statements

              Consolidated Balance Sheets as of June 30, 2004 (unaudited)
              and December 31, 2003 ..............................................       3

              Consolidated Statements of Operations (unaudited) for the
              Three and Six Months Ended June 30, 2004 and 2003 ..................       4

              Consolidated Statements of Cash Flows (unaudited) for the
              Six Months Ended June 30, 2004 and 2003 ............................       5

              Notes to Consolidated Financial Statements (unaudited) .............      6-9

ITEM 2 -- Management's Discussion and Analysis of Financial
              Condition and Results of Operations ................................     10-13

ITEM 3 -- Quantitative and Qualitative Disclosures About Market Risk .............     13-14

ITEM 4 -- Controls and Procedures ................................................      14

PART II -- OTHER INFORMATION

ITEM 1 -- Legal Proceedings ......................................................      15

ITEM 2 -- Changes in Securities and Use of Proceeds ..............................      15

ITEM 3 -- Defaults Upon Senior Securities ........................................      15

ITEM 4 -- Submission of Matters to a Vote of Security Holders ....................      15

ITEM 5 -- Other Information ......................................................      15

ITEM 6 -- Exhibits and Reports on Form 8-K .......................................      15

Signature Page ...................................................................      16

Exhibit 31.1  Certification of Chief Executive Officer Pursuant to Rule 13a-14
              of the Securities Exchange Act of 1934, as Adopted Pursuant to
              Section 302 of The Sarbanes-Oxley Act Of 2002.......................      17

Exhibit 31.2  Certification of Chief Financial Officer Pursuant to Rule 13a-14
              of the Securities Exchange Act of 1934, as Adopted Pursuant to
              Section 302 of The Sarbanes-Oxley Act Of 2002.......................      18

Exhibit 32.1  Certification of Chief Executive Officer Pursuant to 18 U.S.C.
              Section 1350, as Adopted Pursuant to Section 906 of The
              Sarbanes-Oxley Act Of 2002..........................................      19

Exhibit 32.2  Certification of Chief Financial Officer Pursuant to 18 U.S.C.
              Section 1350, as Adopted Pursuant to Section 906 of The
              Sarbanes-Oxley Act Of 2002..........................................      20
</TABLE>


                                       2
<PAGE>

                                  SPEEDUS CORP.
                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                         June 30,      December 31,
                                                                           2004            2003
                                                                       ------------    ------------
                                                                       (unaudited)
<S>                                                                    <C>             <C>
                             ASSETS
Current assets:
    Cash and cash equivalents                                          $ 27,203,635    $ 19,419,197
    Marketable securities                                                    71,740       2,086,638
    Due from broker                                                         793,236       3,713,146
    Prepaid expenses and other                                              156,300          83,222
    Accounts and other receivables                                           63,678          42,500
                                                                       ------------    ------------
    Total current assets                                                 28,288,589      25,344,703
Property and equipment, net of accumulated
  depreciation of $2,221,418 and $2,003,862                                 669,820         419,868
Other intangible assets, net of accumulated
  amortization of $1,426,183 and $1,051,493                               1,667,361       2,042,051
Goodwill                                                                    620,875         620,875
Other investment                                                            600,000              --
Other assets                                                                 83,854          82,563
                                                                       ------------    ------------
    Total assets                                                       $ 31,930,499    $ 28,510,060
                                                                       ============    ============

    LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
    Accounts payable                                                   $    203,046    $    151,258
    Accrued liabilities                                                   1,057,188       1,432,426
    Securities sold and not purchased                                       605,500       5,406,135
                                                                       ------------    ------------
    Total current liabilities                                             1,865,734       6,989,819

Minority interest                                                           198,843         531,055

Commitments and Contingencies

Stockholders' equity:
    Common stock ($.01 par value; 50,000,000
      shares authorized; 21,587,674 and 21,516,088                          215,877         215,161
      shares issued)
    Preferred stock ($.01 par value; 20,000,000 shares authorized):
         Series A Junior Participating ($.01 par value; 4,000 shares
           authorized; no shares issued and outstanding)                         --              --
    Additional paid-in-capital                                           90,534,759      90,442,120
    Treasury stock (at cost; 5,367,349 and 5,257,649 shares)             (5,496,829)     (5,250,552)
    Accumulated deficit                                                 (55,387,885)    (64,417,543)
                                                                       ------------    ------------
    Stockholders' equity                                                 29,865,922      20,989,186
                                                                       ------------    ------------
    Total liabilities and stockholders' equity                         $ 31,930,499    $ 28,510,060
                                                                       ============    ============
</TABLE>

  The accompanying notes are an integral part of these consolidated financial
                                  statements.


                                       3
<PAGE>

                                  SPEEDUS CORP.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (unaudited)

<TABLE>
<CAPTION>
                                            Three months ended June 30,      Six months ended June 30,
                                           ----------------------------    ----------------------------
                                               2004            2003            2004            2003
                                           ------------    ------------    ------------    ------------
<S>                                        <C>             <C>             <C>             <C>
Revenues                                   $    200,228    $    204,267    $    351,243    $    374,074
                                           ------------    ------------    ------------    ------------

Expenses:
     Selling, general and administrative      1,169,568       1,148,804       2,162,282       2,075,387
     Technology settlement expenses                   0               0       2,928,583               0
     Research and development                   368,249         422,723         738,994         757,667
     Depreciation and amortization              306,770         260,245         592,246         475,613
     Cost of sales                               83,567          79,481         128,511         127,781
                                           ------------    ------------    ------------    ------------
     Total operating expenses                 1,928,154       1,911,253       6,550,616       3,436,448
                                           ------------    ------------    ------------    ------------

Operating loss                               (1,727,926)     (1,706,986)     (6,199,373)     (3,062,374)

Gain from technology settlement                       0               0      15,000,000               0
Investment income/(loss)                        154,941      (4,450,651)       (103,181)     (4,498,181)
Minority interest                               190,841         224,680         332,212         305,931
Equity in loss of associated company                  0               0               0         (92,996)
                                           ------------    ------------    ------------    ------------

Net earnings/(loss)                        $ (1,382,144)   $ (5,932,957)   $  9,029,658    $ (7,347,620)
                                           ============    ============    ============    ============

Per share:
Basic earnings/(loss) per common share     $      (0.09)   $      (0.36)   $       0.55    $      (0.44)
                                           ============    ============    ============    ============
Weighted average common shares
    outstanding - basic                      16,255,244      16,623,149      16,271,615      16,752,374
                                           ============    ============    ============    ============

Diluted earnings/(loss) per common share   $      (0.09)   $      (0.36)   $       0.54    $      (0.44)
                                           ============    ============    ============    ============
Weighted average common shares
    outstanding - diluted                    16,255,244      16,623,149      16,832,814      16,752,374
                                           ============    ============    ============    ============
</TABLE>

  The accompanying notes are an integral part of these consolidated financial
                                  statements.


                                       4
<PAGE>

                                  SPEEDUS CORP.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (unaudited)


<TABLE>
<CAPTION>
                                                                       Six months ended June 30,
                                                                      ----------------------------
                                                                          2004            2003
                                                                      ------------    ------------
<S>                                                                   <C>             <C>
Cash flows from operating activities:
     Net earnings/(loss)                                              $  9,029,658    $ (7,347,620)
     Adjustments to reconcile net earnings/(loss) to
       net cash provided by/(used in) operating activities:
         Depreciation and amortization                                     592,246         475,613
         Unrealized investment losses                                       58,237       4,200,710
         Equity in loss of associated company                                   --          92,996
         Minority interest                                                (332,212)       (305,931)
         Stock based compensation                                           21,769              --
         Changes in operating assets and liabilities:
            Marketable securities                                        1,993,673         737,138
            Due from broker                                              2,919,910        (691,530)
            Accounts and other receivables                                 (21,178)         (2,401)
            Prepaid expenses and other                                     (73,078)        (71,312)
            Other assets                                                    (1,291)       (154,360)
            Accounts payable                                                51,788        (111,847)
            Accrued liabilities                                           (375,238)       (193,764)
            Securities sold and not purchased                           (4,837,647)     (2,499,630)
            Other current liabilities                                           --           4,016
                                                                      ------------    ------------

                Net cash provided by/(used in) operating activities      9,026,637      (5,867,922)
                                                                      ------------    ------------

Cash flows from investing activities:
     Property and equipment additions                                     (467,508)        (33,404)
     Other investment                                                     (600,000)             --
     Loans and other receivables, net of repayments                             --           2,500
     Acquisition of business, net of cash acquired                              --          18,798
                                                                      ------------    ------------

                Net cash used in investing activities                   (1,067,508)        (12,106)
                                                                      ------------    ------------

Cash flows from financing activities:
     Proceeds from exercise of options or warrants                          71,586          43,313
     Repurchase of stock                                                  (246,277)       (629,695)
                                                                      ------------    ------------

                Net cash used in financing activities                     (174,691)       (586,382)
                                                                      ------------    ------------

                Net increase/(decrease) in cash
                   and cash equivalents                                  7,784,438      (6,466,410)

Cash and cash equivalents, beginning of period                          19,419,197      33,052,815
                                                                      ------------    ------------

Cash and cash equivalents, end of period                              $ 27,203,635    $ 26,586,405
                                                                      ============    ============

Supplemental information of business acquired:
     Fair value of assets acquired:
         Cash                                                         $         --    $     18,798
         Non current assets                                                     --          34,283
         Goodwill                                                               --         481,009
     Less-liabilities assumed:
         Current liabilities                                                    --        (218,946)
         Minority interest                                                      --        (315,144)
                                                                      ------------    ------------
     Cash paid                                                                  --              --
         less-cash acquired                                                     --          18,798
                                                                      ------------    ------------
     Acquisition of business, net of cash acquired                    $         --    $    (18,798)
                                                                      ============    ============
</TABLE>

  The accompanying notes are an integral part of these consolidated financial
                                  statements.


                                       5
<PAGE>

                                  SPEEDUS CORP.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)

1. Basis of Presentation

      The unaudited consolidated financial statements of Speedus Corp. have been
prepared in accordance with generally accepted accounting principles for interim
financial information. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have
been included. These financial statements do not include all information and
notes required by generally accepted accounting principles for complete
financial statements. These financial statements should be read in conjunction
with the Company's 2003 audited consolidated financial statements and notes
thereto on Form 10-K.

      Operating results for the three and six months ended June 30, 2004 are not
necessarily indicative of the results that may be expected for the year ending
December 31, 2004.

Financial statements and principles of consolidation

      The consolidated financial statements include the accounts of Speedus and
its wholly-owned subsidiaries. All significant intercompany accounts and
transactions have been eliminated in consolidation.

      Companies in which Speedus directly or indirectly owns more than 50% of
the outstanding voting securities or that Speedus has effective control over are
accounted for under the consolidation method of accounting. Under this method,
those companies' balance sheets and results of operations, from the date Speedus
acquired control, are included in Speedus' consolidated financial statements.
The interest in the net assets and operations of these companies' other
stockholders is reflected in the caption `Minority interest' in Speedus'
consolidated balance sheet and statements of operations.

      The Company's share of earnings or losses of associated companies, that
are 20% to 50% owned, is included in the consolidated operating results using
the equity method of accounting.

      Companies in which Speedus owns less than 20% of the outstanding voting
securities and does not have the ability to exercise significant influence are
accounted for under the cost method of accounting.

Estimates

      The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the dates of the financial
statements and the reported amounts of operating revenues and expenses during
the reporting periods. Actual results could differ from those estimates and the
difference could be material.

Marketable Securities

      All marketable securities are defined as trading securities under the
provisions of Statement of Financial Accounting Standards No. 115, "Accounting
for Certain Investments in Debt and Equity Securities." At June 30, 2004 and
December 31, 2003, marketable securities consisted of publicly traded equity
securities and were recorded at fair market value. Their original cost was
$663,000 and $2,040,000, unrealized gains/(losses) since acquisition were
$(591,000) and $47,000 and the fair market value was $72,000 and $2,087,000,
respectively. At June 30, 2004, based upon the fair market value of these
securities, 100% was invested in technology companies.

Other investment

      At June 30, 2004, other investment consisted of a convertible promissory
note in a non-public drug delivery technology company and is recorded at cost.
In connection with this investment, the Company also received warrants to
purchase 300,000 shares of common stock at $1 per share, subject to adjustment
under certain circumstances. The Company expects that the promissory note will
be converted into common shares of the debtor company, under a formula subject
to certain terms and conditions.

Securities Sold But Not Purchased

      The Company may sell publicly traded equity securities it does not own in
anticipation of declines in the fair market values of the securities. When the
Company effects such transactions, it must borrow the securities it sold in
order to deliver them and settle the trades. The amounts shown on the balance
sheet as `Securities sold and not purchased' represent the value of these
securities at fair market value. At June 30, 2004 and December 31, 2003, the
Company had sold securities it had not purchased. The aggregate proceeds were
$568,000 and $4,514,000, unrealized losses since acquisition were $38,000 and
$892,000 and the fair market value of the securities was $606,000 and
$5,406,000, respectively. At June 30, 2004, based upon the fair market value of
these securities, 100% was invested in the airline industry.


                                       6
<PAGE>

Due From Broker

      In connection with selling publicly traded securities that it does not
own, the Company is obligated to maintain balances with brokerage firms as
security for these transactions. At June 30, 2004 and December 31, 2003,
restricted cash balances in the amounts of $793,000 and $3,713,000,
respectively, were held by brokerage firms.

Concentrations of Credit Risk

      Financial instruments that potentially could subject the Company to
concentrations of credit risk consist largely of cash and cash equivalents,
amounts due from brokers and marketable securities. These instruments are
potentially subject to concentrations of credit risk but the Company believes
that this risk is limited due to diversification and investments being made in
investment grade securities.

      The Company also sells publicly traded equity securities that it does not
own in anticipation of declines in the fair market values of the securities.
When the Company sells securities that it does not own, it must borrow the
securities it sold in order to deliver them and settle the trades. Thereafter,
the Company must buy the securities and deliver them to the lender of the
securities. The Company's potential for loss on these transactions is unlimited
since the value of the underlying security can keep increasing which could have
a material adverse effect on the Company's consolidated financial statements.

Long-lived Assets

      The Company periodically evaluates the net realizable value of long-lived
assets, including fixed and intangible assets, relying on anticipated future
cash flows. The Company's evaluation of anticipated future cash flows considers
operating results, business plans and economic projections, as well as,
non-financial data such as market trends, product and development cycles, and
changes in management's market emphasis. An impairment in the carrying value of
an asset is recognized when the expected future operating cash flows derived
from the asset are less than its carrying value.

Goodwill and Other Intangible Assets

      The Company accounts for goodwill and other intangible assets in
accordance with Statement of Financial Accounting Standards No. 142, "Goodwill
and Other Intangible Assets" which requires the use of a nonamortization
approach to account for purchased goodwill and certain intangibles. Under the
nonamortization approach, goodwill is not being amortized into results of
operations, but instead is reviewed for impairment at least annually and charged
against results of operations only in the periods in which the recorded value of
goodwill and certain intangibles is more than its fair value. Goodwill in
connection with the acquisition of F&B Gudtfood had a balance of $621,000 at
December 31, 2003 and June 30, 2004.

      Other intangible assets consist of: (i) the cost of a broadband patent and
(ii) medical technology in connection with the acquisition of a controlling
interest in Zargis Medical. The broadband patent, in the aggregate amount of
$2,070,000 with accumulated amortization in the amount of $1,038,000 at June 30,
2004, is being amortized over a period of four years. Medical technology, in the
aggregate amount of $1,024,000 with accumulated amortization in the amount of
$388,000 at June 30, 2004, is being amortized over a period of three years.

      For the three and six months ended June 30, 2004, amortization expense
relating to intangible assets was $187,000 and $375,000, respectively. For the
three and six months ended June 30, 2003, amortization expense relating to
intangible assets was $157,000 and $260,000, respectively. The estimated
amortization of intangible assets for the balance of fiscal 2004 and fiscal
years 2005 and 2006, the expiration of the remaining useful life of the
Company's intangible assets, is $375,000, $749,000 and $543,000, respectively.

Revenue Recognition

      Revenues from F&B Gudtfood's operations are recorded on a cash basis.

Earnings Per Share

      Basic and diluted earnings/(loss) per common share are determined in
accordance with Statement of Financial Accounting Standards No. 128, "Earnings
Per Share".

      For the six months ended June 30, 2004, the weighted average common shares
for diluted earnings per share were determined by adding weighted average shares
in the aggregate amount of 561,199 for the assumed exercise of stock options and
warrants, calculated using the treasury stock method, to the weighted average
shares outstanding for basic earnings per share for a total of 16,832,814
weighted average shares outstanding for diluted earnings per share. For the
three and six months ended June 30, 2004 and the three and six months ended June
30, 2003, outstanding stock options and warrants in the weighted average amount
of 1,828,358, 852,165, 2,135,934 and 2,049,449, respectively, have been excluded
from the diluted loss per share since their effect would be antidilutive.

Stock Options

      The Company accounts for its employee stock options in accordance with
Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation", as amended by SFAS 148, "Accounting for Stock-Based
Compensation--Transition and Disclosure--an amendment of FASB Statement No.
123", which defines a "fair value method" of measuring and accounting for
compensation expense from employee stock options. This standard also allows
accounting for such options under the "intrinsic value method" in accordance
with Accounting Principles Board No. 25, "Accounting for Stock Issued to
Employees." The


                                       7
<PAGE>

Company has elected to use the intrinsic value method and is presenting pro
forma disclosures of earnings and earnings per share as if the fair value method
of accounting was applied.

      Unaudited pro forma earnings information giving effect to compensation
expense based upon the fair value at the date of grant in accordance with SFAS
123 for the three and six months ended June 30, 2004 and 2003 is summarized as
follows:

<TABLE>
<CAPTION>
                                             Three months ended June 30,      Six months ended June 30,
                                             ----------------------------    ---------------------------
                                                     (unaudited)                     (unaudited)
                                                 2004            2003            2004           2003
                                             ------------    ------------    ------------   ------------
<S>                                          <C>             <C>             <C>            <C>
Net earnings/(loss) as reported              $ (1,382,144)   $ (5,932,957)   $  9,029,658   $ (7,347,620)
After tax effect of pro forma compensation         (4,750)        (73,737)         (4,750)      (195,931)
                                             ------------    ------------    ------------   ------------
Pro forma net earnings/(loss)                $ (1,386,894)   $ (6,006,694)   $  9,024,908   $ (7,543,551)
                                             ============    ============    ============   ============
Earnings/(loss) per share:
Basic - as reported                          $      (0.09)   $      (0.36)   $       0.55   $      (0.44)
                                             ============    ============    ============   ============
Basic - pro forma                            $      (0.09)   $      (0.36)   $       0.55   $      (0.45)
                                             ============    ============    ============   ============
Diluted - as reported                        $      (0.09)   $      (0.36)   $       0.54   $      (0.44)
                                             ============    ============    ============   ============
Diluted - pro forma                          $      (0.09)   $      (0.36)   $       0.54   $      (0.45)
                                             ============    ============    ============   ============
</TABLE>

2. Acquisitions

      a. On February 28, 2003, the Company increased its investment in Zargis
Medical to 57.7% with an additional investment of $1,250,000. Prior to February
28, 2003, the Company held a 46.4% interest in Zargis and accounted for its
investment under the equity method of accounting. On July 28, 2003, the Company
increased its ownership in Zargis Medical to 68.9% with an additional investment
of $2,000,000. As of December 31, 2003 and February 1, 2004, our ownership
increased to 70.5% and 71.2%, respectively, as a result of certain milestones
not having been met.

      This acquisition was accounted for using the purchase method of
accounting. The results of operations of Zargis Medical have been included in
the consolidated statements of operations from the date of acquisition. The
$3,250,000 aggregate purchase price was allocated as follows: $3,269,000 to
cash, $34,000 to non current assets, $1,024,000 to other intangible assets,
$(219,000) to current liabilities and $(858,000) to minority interest. An
aggregate of $1,024,000, representing the excess of the purchase price over the
fair value of the net assets acquired, has been allocated as medical technology
to an intangible asset and will be amortized over a period of three years.

      Unaudited pro forma operating results of the Company for the six months
ended June 30, 2003, as though the acquisition of Zargis Medical had occurred on
January 1, 2003, are as follows:

                Revenues                           $   374,074
                Operating loss                     $(3,262,797)
                Net loss                           $(7,370,268)
                Basic and diluted loss per share   $     (0.44)

      b. On May 6, 2002, the Company acquired a 51% interest in F&B Gudtfood,
the creator and operator of the original Eurocentric "chic and quick" cafe,
which is operating two stores in Manhattan. The acquisition price was
$3,500,000. On February 8, 2003, the Company reduced its cash investment in F&B
Gudtfood and received $1,775,000 while maintaining its 51% interest. In December
2003, as a result of renegotiation, our interest increased to 80% without an
additional investment.

3. Stockholders' Equity

Treasury Stock

      In March 2003, the Company's Board of Directors approved an extension of
the Company's stock repurchase program for up to an additional $1 million of the
Company's common stock for an aggregate authorization of $5.5 million. As of
June 30, 2004 and through August 14, 2004, the Company has repurchased 5,367,349
shares of its Common Stock for an aggregate cost of $5,497,000.

4. Gain from Technology Settlement

      In February 2004, the Company's wholly-owned subsidiary, CellularVision
Technology & Telecommunications, L.P. (CT&T), received $15 million from a former
international licensee in settlement of litigation that CT&T instituted in May
2001.

      In connection with the settlement and as provided under the terms of his
2002 employment agreement, Shant S. Hovnanian, Chairman of the Board and Chief
Executive Officer of the Company, received a contingent participation in the
proceeds of the settlement in the amount of approximately $2.8 million. In
addition, approximately $0.1 million in legal and other closing costs was


                                       8
<PAGE>

paid at closing to unaffiliated third parties. These expenses are included in
Technology Settlement Expenses for the six months ended June 30, 2004 in the
accompanying consolidated statement of operations.

5. Business Segment Information

      The following table sets forth the Company's financial performance by
reportable operating segment for the three and six months ended June 30, 2004
and 2003. F&B Gudtfood and Zargis Medical are included in the consolidated
financial statements of the Company since May 6, 2002 and February 28, 2003,
respectively, the dates of acquisition of majority interests.

<TABLE>
<CAPTION>
                                                       Three months ended June 30, 2004
                                             --------------------------------------------------------
                                                                        Corporate
                                                F&B        Zargis       and other         Totals
                                                ---        ------       ---------         ------
<S>                                          <C>          <C>          <C>             <C>
      Revenues from external customers       $ 200,228    $       0    $          0    $    200,228
      Depreciation and amortization             25,762        4,211         276,797         306,770
      Operating loss                          (267,627)    (512,710)       (947,589)     (1,727,926)
      Investment income/(loss)                     602        1,284         153,055         154,941
      Goodwill and other intangible assets     620,875      635,441       1,031,920       2,288,236
      Fixed assets                             533,872       30,136         105,812         669,820
      Total assets                             657,259      411,016      30,862,224      31,930,499

<CAPTION>

                                                         Three months ended June 30, 2003
                                             ---------------------------------------------------------
                                                                          Corporate
                                                 F&B         Zargis       and other         Totals
                                                 ---         ------       ---------         ------
<S>                                          <C>            <C>          <C>             <C>
      Revenues from external customers       $   203,387    $       0    $        880    $    204,267
      Depreciation and amortization                6,200        3,108         250,937         260,245
      Operating loss                            (128,165)    (395,388)     (1,183,433)     (1,706,986)
      Investment income/(loss)                     3,643            0      (4,454,294)     (4,450,651)
      Goodwill and other intangible assets       890,356      427,563       1,444,687       2,762,606
      Fixed assets                               137,300      229,086         301,475         667,861
      Total assets                             1,330,893      604,596      41,010,815      42,946,304

<CAPTION>

                                                        Six months ended June 30, 2004
                                             -------------------------------------------------------
                                                                        Corporate
                                                F&B        Zargis       and other         Totals
                                                ---        ------       ---------         ------
<S>                                          <C>          <C>          <C>             <C>
      Revenues from external customers       $ 349,572    $       0    $      1,671    $    351,243
      Depreciation and amortization             35,799        7,318         549,129         592,246
      Operating loss                          (391,763)    (886,206)     (4,921,404)     (6,199,373)
      Investment income/(loss)                   1,993        4,198        (109,372)       (103,181)

<CAPTION>

                                                        Six months ended June 30, 2003
                                             -------------------------------------------------------
                                                                        Corporate
                                                F&B        Zargis       and other         Totals
                                                ---        ------       ---------         ------
<S>                                          <C>          <C>          <C>             <C>
      Revenues from external customers       $ 371,838    $       0    $      2,236    $    374,074
      Depreciation and amortization             12,400        3,864         459,349         475,613
      Operating loss                          (212,256)    (533,731)     (2,316,387)     (3,062,374)
      Investment income/(loss)                  11,342            0      (4,509,523)     (4,498,181)
</TABLE>

      The Company has no foreign operations. During the three and six months
ended June 30, 2004 and 2003, the Company did not have sales to any individual
customer greater than 10% of total Company revenues. The Company's accounting
policies for segments are the same as those described in Note 1.

6. Legal Proceedings

      The Company is subject to various claims and proceedings that occur in the
ordinary course of business. The Company believes it has substantial defenses to
a material portion of these claims and is prepared to pursue litigation if a
reasonable and structured settlement cannot be reached with the parties. Based
on information currently available, the Company believes it is remote that the
ultimate resolution of these current claims or proceedings, either individually
or in the aggregate, will have a material effect on its financial position,
results of operations or cash flows.


                                       9
<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

      The following discussion and analysis of financial condition and results
of operations should be read in conjunction with the corresponding discussion
and analysis included in the Company's Report on Form 10-K for the year ended
December 31, 2003.

Cautionary Statement Regarding Forward-Looking Information

      This Management's Discussion and Analysis of Financial Condition and
Results of Operations and other sections of this Form 10-Q contain
"forward-looking statements" within the meaning of Section 27A of the Securities
Act and Section 21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"). These statements appear in a number of places in this Form 10-Q
and include statements regarding the intent, belief or current expectations of
the Company or its officers with respect to, among other things, the ability of
the Company to make capital expenditures, the ability to incur additional debt,
as necessary, to service and repay such debt, if any, as well as other factors
that may effect the Company's financial condition or results of operations.
Forward-looking statements may include, but are not limited to, projections of
revenues, income or losses, capital expenditures, plans for future operations,
financing needs or plans, compliance with covenants in loan agreements, plans
for liquidation or sale of assets or businesses, plans relating to products or
services of the Company, assessments of materiality, predictions of future
events, and the ability to obtain additional financing, including the Company's
ability to meet obligations as they become due, and other pending and possible
litigation, as well as assumptions relating to the foregoing. All statements in
this Form 10-Q regarding industry prospects and the Company's financial position
are forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. Although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, it can give no assurance that such
expectations will prove to have been correct. The Company undertakes no
obligation to publicly release the result of any revisions to these
forward-looking statements that may be made to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.

Business Activities

      Speedus Corp. is a holding company that owns significant equity interests
in diverse businesses. We seek business opportunities across all industries for
potential transactions and relationships in which we can apply our current
resources and management strengths. The companies that we target, either public
or privately held, will be seeking growth or restructuring capital to pursue
near term business objectives in demonstrated markets. We will continue to
pursue opportunities involving our expertise in the medical device and wireless
markets as well as those areas involving our broadband assets as attractive
opportunities present themselves.

      We have co-invested with Siemens Corporate Research, Inc., a subsidiary of
Siemens Corporation, in Zargis Medical Corp. to develop medical diagnostic
support service solutions that automatically analyze acoustical data from a
patient to determine physiological significant features useful in medical
diagnosis. The first Zargis clinical device, the Zargis Acoustic Cardioscan,
received FDA approval in May 2004. Cardioscan will initially be launched to a
select group of physicians, teaching hospitals and other health care
professionals. We own 80% of F&B Gudtfood Holding Corp., the creator and
operator of the original Eurocentric "chic and quick" cafe, which is operating
two stores in Manhattan. We own a portfolio of patents that allow for high-speed
wireless communications. We also own fixed wireless spectrum in the New York
City metropolitan area that we may commercialize in the future to support
high-speed, or broadband, Internet access service.

      Zargis Medical Corp. In January 2001, we co-invested with Siemens
Corporate Research, Inc., a subsidiary of Siemens Corporation, in Zargis Medical
Corp. to develop non-invasive, medical diagnostic support solutions that
automatically analyze acoustical data from a patient to determine
physiologically significant features useful in medical diagnosis. The
development of Zargis' patented technology is a pioneering effort in medicine
which uses advanced signal processing algorithms deployed on standard computer
platforms. The first Zargis device, the Zargis Acoustic Cardioscan, received FDA
approval in May 2004. Cardioscan will initially be launched to a select group of
physicians, teaching hospitals and other health care professionals to be used as
part of general medical examinations and physicals to detect murmurs which could
be a sign of valvular and congenital heart disease. General medical
examinations, according to the National Center for Health Statistics, totaled 64
million in 2000 for the US alone. Zargis is currently researching, and
conducting trials on, additional noninvasive diagnostic support tools that
process acoustical data from the body in order to provide an accurate and
intelligible assessment of a patient's health. These assessments may be used by
physicians and other healthcare providers to assist in the early identification
or monitoring of heart, lung, vascular and other conditions and to provide
better patient treatment.

      We have signed an exclusive contract with Zargis to provide transaction
processing to support Zargis' medical products. Some of the major next steps
remaining for Zargis include continuing clinical trials for new applications of
the Zargis technology and the formation of strategic partnerships for industry
and market acceptance.

      In February 2003, we acquired a controlling interest in Zargis Medical for
an additional investment of $1,250,000. In July 2003, we increased our ownership
in Zargis Medical to 68.9% by investing an additional $2,000,000. As of December
31, 2003 and February 1, 2004, our ownership increased to 70.5% and 71.2%,
respectively, as a result of certain milestones not having been met.


                                       10
<PAGE>

      F&B Gudtfood. We own 80% of F&B Gudtfood, the creator and operator of the
original Eurocentric "chic and quick" cafe, which is operating two stores in
Manhattan. The acquisition price was $3,500,000 in May 2002. In February 2003,
we reduced our cash investment in F&B Gudtfood and received $1,775,000 while
maintaining our original 51% interest. In December 2003, as a result of
renegotiation, our interest increased to 80% without an additional investment
and, under certain circumstances, could increase to 90%. We expect that F&B
Gudtfood will begin selling F&B Gudtfood franchises through its wholly owned
subsidiary, F&B Gudtfood Franchise Corp., in the third quarter of 2004. We have
also entered into a management services contract with F&B Gudtfood.

      Broadband Patents. Through our wholly owned subsidiaries, Broadband
Patents, LLC and CellularVision Technology & Telecommunications, L.P., we have
accumulated a portfolio of patents that allow for high-speed wireless
communication systems with greater information content, reliability, clarity, or
more efficient use of licensed spectrum as compared to prior systems. We have
six domestic patents with expiration dates ranging from 2007 through 2017, with
approximately 60 international counterparts in 42 countries. Certain wireless
communications systems may employ a number of different combinations of our
patented technology to maximize operational and spectrum efficiency. While we
believe that it would be difficult for such a wireless communications system to
be constructed without using one or more of our patented technologies, it is a
lengthy and expensive process to pursue licensing/patent infringement cases. We
are evaluating a strategy for the utilization of these patents in the future,
which may include pursuit of licensing or development of other strategic
opportunities with users of the underlying technology. However, due to the
current depressed economic state of the telecommunications industry, licensing
activity for the patent portfolio is not actively being pursued at this time. We
have licensed technology in the past, both domestically and internationally, but
are not currently receiving any license fees.

      Local Multipoint Distribution Service (LMDS) license. We have an FCC
commercial operating license, awarded to us in recognition of our efforts in
developing and deploying LMDS technology and for spearheading its regulatory
approval at the FCC, which covers 150 MHz of spectrum in the New York City area.
The license has been renewed as a standard LMDS license through February 1,
2006. Under FCC authorization, the license includes an additional 150 MHz of
spectrum until the first Ka band satellite is launched, an event which is not
currently determinable. The license provides that the spectrum may be used for a
wide variety of fixed wireless purposes, including wireless local loop
telephony, high-speed Internet access and two-way teleconferencing.

      We will not commence a full marketing effort using our LMDS technology
until new LMDS equipment becomes commercially available with cost and
performance that allow implementation of an economically viable business model.
We cannot determine when this will occur and this equipment may never be
available to us on this basis.

      Other. We have invested a portion of our assets in a portfolio of
marketable securities consisting of publicly traded equity securities. We have
also sold publicly traded equity securities we do not own in anticipation of
declines in the fair market values of these securities.

      We have generated operating losses and negative operating cash flows since
our inception and expect to continue to do so in the near future.

Critical Accounting Policies

      Our discussion and analysis of our financial condition and results of
operations are based upon our consolidated financial statements. The preparation
of those financial statements in conformity with generally accepted accounting
principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the dates of the financial statements and the reported
amounts of operating revenues and expenses during the reporting periods. Actual
results could differ from those estimates. For a description of all of our
accounting policies, see Note 1 to our consolidated financial statements
included in this Form 10-Q and Note 2 to our consolidated financial statements
included in our 2003 Form 10-K. However, we believe the following critical
accounting policies affect the more significant judgments and estimates used in
the preparation of our consolidated financial statements.

      Financial instruments. Our financial instruments consist primarily of cash
and cash equivalents, marketable securities, amounts due from brokers and
securities sold and not purchased. The carrying value of cash equivalents
approximates market value since these highly liquid, interest earning
investments are invested in money market funds. Marketable securities consist of
publicly traded equity securities classified as trading securities and are
recorded at fair market value, i.e., closing prices quoted on established
securities markets. Securities sold and not repurchased are also carried at the
fair market value of the securities. Significant changes in the market value of
securities that we invest in could have a material impact on our financial
position and results of operations.

      Long-lived assets. Long-lived assets, including fixed assets, goodwill and
other intangibles, are reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of any such asset may not be
recoverable through estimated future cash flows from that asset. The estimate of
cash flow is based upon, among other things, certain assumptions about expected
future operating performance. Specifically, we own a broadband patent, included
in intangible assets, which had a carrying value of $1.2 million and $1.0
million at December 31, 2003 and June 30, 2004, respectively, and currently do
not generate any revenues or cash flows. However, as of December 31, 2003, we
estimated that, based upon our review of recent transactions and other factors,
the fair value of our remaining FCC license and certain patents that have no
carrying value on our books would generate sufficient cash to fully


                                       11
<PAGE>

realize this asset as of December 31, 2003. This estimate evaluated the recovery
of this broadband asset compared to the fair value of our remaining FCC license
and certain patents as a group since it represents the lowest level for which
identifiable cash flows are largely independent of the cash flows of other
groups of assets and liabilities. These estimates may differ from actual results
due to, among other things, technological changes, economic conditions, changes
to our business model or changes in our operating performance.

      Goodwill is reviewed for impairment at least annually. As of December 31,
2003, we reviewed the carrying value of goodwill in the amount of $0.6 million
at that time, and estimated based upon our review, taking into account such
factors as projected operations and Company's redemption rights in connection
with the investment, that there had been no impairment to this carrying value.

      Contingencies. We account for contingencies in accordance with Statement
of Financial Accounting Standards No. 5, "Accounting for Contingencies". SFAS
No. 5 requires that we record an estimated loss when information available prior
to issuance of our financial statements indicates that it is probable that an
asset has been impaired or a liability has been incurred at the date of the
financial statements and the amount of the loss can be reasonably estimated.
Accounting for contingencies such as environmental, legal and income tax matters
requires us to use our judgment. While we believe that our accruals for these
matters are adequate, if the actual loss is significantly different than the
estimated loss, our results of operations will be affected in the period that
the difference is known.

Six and Three Months Ended June 30, 2004 Compared to Six and Three Months Ended
June 30, 2003

      Revenues decreased $23,000 from $374,000 for the six months ended June 30,
2003 to $351,000 for the six months ended June 30, 2004 and decreased $4,000
from $204,000 for the three months ended June 30, 2003 to $200,000 for the three
months ended June 30, 2004. These decreases are primarily a result of
unfavorable weather conditions, decreasing store traffic. The decrease for the
six month periods is net of an increase in the amount of $33,000 as a result of
the opening of a second F&B Gudtfood store during the three and six months ended
June 30, 2004.

      Selling, general and administrative expenses increased $87,000 from
$2,075,000 for the six months ended June 30, 2003 to $2,162,000 for the six
months ended June 30, 2004 and increased $21,000 from $1,149,000 for the three
months ended June 30, 2003 to $1,170,000 for the three months ended June 30,
2004. These increases are primarily a result of an increase in selling, general
and administrative expenses of Zargis Medical. Zargis Medical is included in the
consolidated financial statements of the Company since February 28, 2003, the
date of acquisition of a majority interest. Selling, general and administrative
expenses also increased by $109,000 during the three months ended June 30, 2004
as a result of the opening of a second F&B Gudtfood store. The increases for
these periods are net of decreases in compensation and employee related expenses
as a result of staff reductions by Speedus.

      During the six months ended June 30, 2004, the Company incurred $2,929,000
in expenses in connection with a technology settlement in the amount of
$15,000,000. In connection with the settlement and as provided under the terms
of his 2002 employment agreement, Shant S. Hovnanian, Chairman of the Board and
Chief Executive Officer of the Company, received a contingent participation in
the proceeds of the settlement in the amount of approximately $2.8 million
during the six months ended June 30, 2004.

      Research and development expenses decreased $19,000 from $758,000 for the
six months ended June 30, 2003 to $739,000 for the six months ended June 30,
2004 and decreased $55,000 from $423,000 for the three months ended June 30,
2003 to $368,000 for the three months ended June 30, 2004. These decreases are
primarily a result of decreases in compensation and employee related expenses as
a result of staff reductions by Speedus, net of increases in research and
development expenses of Zargis Medical. Zargis Medical is included in the
consolidated financial statements of the Company since February 28, 2003, the
date of acquisition of a majority interest.

      Depreciation and amortization increased $116,000 from $476,000 for the six
months ended June 30, 2003 to $592,000 for the six months ended June 30, 2004
and increased $47,000 from $260,000 for the three months ended June 30, 2003 to
$307,000 for the three months ended June 30, 2004. This increase is primarily a
result of the amortization of medical technology during the three and six months
ended June 30, 2004 resulting from the Zargis Medical acquisition.

      During the three and six months ended June 30, 2004, the Company recorded
a gain from technology settlement in the amount of $15,000,000.

      Investment loss decreased $4,395,000 from a loss of $4,498,000 for the six
months ended June 30, 2003 to a loss of $103,000 for the six months ended June
30, 2004 and decreased $4,606,000 from a loss of $4,451,000 for the three months
ended June 30, 2003 to a gain of $155,000 for the three months ended June 30,
2004. These changes are primarily a result of the recognition of realized and
unrealized gains/(losses) during these periods. The Company records marketable
securities and securities sold and not purchased at the fair market value of the
securities. The amount of these realized and unrealized gains or losses will
fluctuate based upon changes in the market value of the underlying investments
and are not necessarily indicative of the results that may be expected for any
future periods. Investment results during the three months ended June 30, 2004
were also impacted by a lower level of investment activity. Future levels of
investment activities will be impacted by opportunities as they arise. Realized
losses decreased $1,032,000 from net losses of $1,434,000 for the six months
ended June 30, 2003 to net losses of $402,000 for the six months ended June 30,
2004. Unrealized losses decreased $3,353,000 from net losses of $3,163,000 for
the six months ended June 30, 2003 to net gains of $190,000 for the six


                                       12
<PAGE>

months ended June 30, 2004.

      Minority interest increased $26,000 from $306,000 for the six months ended
June 30, 2003 to $332,000 for the six months ended June 30, 2004 and decreased
$34,000 from $225,000 for the three months ended June 30, 2003 to $191,000 for
the three months ended June 30, 2004. These amounts represent the interest of
minority stockholders in the losses of F&B Gudtfood and Zargis Medical.

      Equity in loss of associated company amounted to $93,000 for the six
months ended June 30, 2003. This amount reflects the Company's share in Zargis
Medical's operations, accounted for under the equity method, through February
27, 2003. Zargis Medical is included in the consolidated financial statements of
the Company since February 28, 2003, the date of acquisition of a majority
interest. As a result, no amount was recorded for the three and six months ended
June 30, 2004.

Liquidity and Capital Resources

      The Company has recorded operating losses and negative operating cash
flows in each year of its operations since inception.

      Net cash provided by operating activities was $9.0 million for the six
months ended June 30, 2004 compared to net cash used in operating activities of
$5.9 million for the six months ended June 30, 2003. This net increase in cash
provided was primarily the result of a gain from technology settlement in the
amount of $15 million recognized during the six months ended June 30, 2004,
reduced by $2.9 million in technology settlement expenses. In February 2004, the
Company's wholly-owned subsidiary, CellularVision Technology &
Telecommunications, L.P., received $15 million from a former international
licensee in settlement of litigation that CT&T instituted in May 2001. In
connection with the settlement and as provided under the terms of his 2002
employment agreement, Shant S. Hovnanian, Chairman of the Board and Chief
Executive Officer of the Company, received a contingent participation in the
proceeds of the settlement in the amount of approximately $2.8 million during
the six months ended June 30, 2004.

      Net cash used in investing activities was $1.1 million for the six months
ended June 30, 2004 compared to net cash used in investing activities of $12,000
for the six months ended June 30, 2003. This net increase in cash used in
investing activities was the result of property and equipment additions
aggregating $0.5 million and a $0.6 million investment made during the 2004
period. The investment consists of a convertible promissory note in a non-public
drug delivery technology company and is recorded at cost. In connection with
this investment, the Company also received warrants to purchase 300,000 shares
of common stock at $1 per share, subject to adjustment under certain
circumstances. The Company expects that the promissory note will be converted
into common shares of the debtor company, under a formula subject to certain
terms and conditions.

      Net cash used in financing activities was $175,000 for the six months
ended June 30, 2004 compared to net cash used in financing activities of
$586,000 for the six months ended June 30, 2003. This decrease in cash used in
financing activities was primarily the result of decreased repurchases of
treasury stock.

      At June 30, 2004, the Company's future minimum lease payments due under
noncancelable leases aggregated $1,848,000. $377,000, $361,000, $223,000,
$216,000 and $222,000 of this amount is due during the twelve months ending June
30, 2005, 2006, 2007, 2008 and 2009, respectively, and the balance is payable
thereafter.

      The Company believes that it has sufficient liquidity to finance its
current level of operations and expected capital requirements through the next
twelve months. However, the Company does not expect to have earnings from
operations until such time as it substantially increases its customer base
and/or forms a strategic alliance for use of its capabilities in the future. We
cannot predict when this will occur. We have no material non-cancelable
commitments and the amount of future capital funding requirements will depend on
a number of factors that we cannot quantify, including the success of our
business, the extent to which we expand our high-speed Internet service if
suitable equipment becomes available and the types of services we offer, as well
as other factors that are not within our control, including competitive
conditions, government regulatory developments and capital costs. The lack of
additional capital in the future could have a material adverse effect on the
Company's financial condition, operating results and prospects for growth.

      We have invested a portion of our assets in a portfolio of marketable
securities consisting of publicly traded equity securities. We purchase these
securities in anticipation of increases in the fair market values of the
securities. We have also sold publicly traded equity securities we do not own in
anticipation of declines in the fair market values of these securities. When we
sell securities that we do not own, we must borrow the securities we sold in
order to deliver them and settle the trades. Thereafter, we must buy the
securities and deliver them to the lender of the securities. Our potential for
loss on these transactions is unlimited since the value of the underlying
security can keep increasing.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

      The Company's financial instruments at June 30, 2004 consist primarily of
cash and cash equivalents, which are subject to interest rate risk, and
marketable securities and securities sold and not purchased, which are subject
to equity price risk.

      As part of our overall investment strategy, we invest in publicly traded
equity securities. We purchase these securities in anticipation of increases in
the fair market values of the securities. We also sell publicly traded equity
securities that we do not own in anticipation of declines in the fair market
values of the securities. When we sell securities that we do not own, we must
borrow the securities we sold in order to deliver them and settle the trades.
Thereafter, we must buy the securities and deliver them to the lender of the
securities. Our potential for loss on these transactions is unlimited since the
value of the underlying security can keep increasing which could have a material
adverse effect on the Company's consolidated financial statements.

      The carrying value of cash equivalents approximates market value since
these highly liquid, interest earning investments are


                                       13
<PAGE>

invested in money market funds. The Company's investment in marketable
securities consists of publicly traded equity securities classified as trading
securities and are recorded at fair market value. Securities sold and not
repurchased are carried at the fair market value of the securities.

ITEM 4. CONTROLS AND PROCEDURES

      Management of the Company, including the Chief Executive Officer and the
Chief Financial Officer, evaluated the effectiveness of the design and operation
of the Company's disclosure controls and procedures as of the end of the period
covered by this report. Based upon that evaluation, the Company's Chief
Executive Officer and the Chief Financial Officer concluded that the Company's
disclosure controls and procedures were effective as of the end of the period
covered by this report for the information required to be disclosed by the
Company in the reports it files or submits under the Securities Exchange Act of
1934, as amended, to be recorded, processed, summarized and reported within the
time periods specified in the Securities and Exchange Commission's rules and
forms.

      There has been no change in the Company's internal control over financial
reporting during the fiscal quarter ended June 30, 2004 that has materially
affected, or is reasonably likely to materially affect, the Company's internal
control over financial reporting.


                                       14
<PAGE>

                           PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

      The Company is subject to various claims and proceedings that occur in the
ordinary course of business. The Company believes it has substantial defenses to
a material portion of these claims and is prepared to pursue litigation if a
reasonable and structured settlement cannot be reached with the parties. Based
on information currently available, the Company believes it is remote that the
ultimate resolution of these current claims or proceedings, either individually
or in the aggregate, will have a material effect on its financial position,
results of operations or cash flows.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

      Stock repurchase program:

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------
                                                                                             (d) Maximum
                                                                                              number (or
                                                                                             Approximate
                                                                    (c) Total number       Dollar Value) of
                                                                      of Shares (or       Shares (or Un its)
                                                                    Units) Purchased        that May Yet Be
                           (a) Total Number    (b) Average Price   as Part of Publicly      Purchased Under
                            of Shares (or      Paid per Share (or     Announced Plans        the Plans or
      Period               Units) Purchased           Unit)            or Programs            Programs (1)
-------------------------------------------------------------------------------------------------------------
<S>                             <C>                  <C>                  <C>                   <C>
April 1, 2004 -
    April 30, 2004              19,200               $ 2.45               19,200                $158,830
-------------------------------------------------------------------------------------------------------------
May 1 -
    May 31, 2004                74,500                 2.09               74,500                   3,171
-------------------------------------------------------------------------------------------------------------
June 30, 2004 -
    June 30, 2004                    0                    0                    0                   3,171
-------------------------------------------------------------------------------------------------------------
Total                           93,700               $ 2.16               93,700                $  3,171
-------------------------------------------------------------------------------------------------------------
</TABLE>

(1)   On November 21, 2000, the Company announced that its Board of Directors
      had approved a stock repurchase program for the repurchase of up to
      $1,000,000 of Company stock through open market as well as privately
      negotiated transactions. Thereafter, the Board of Directors approved
      increases to the program in the aggregate amount of $4,500,000.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

      None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

      None.

ITEM 5. OTHER INFORMATION

      None.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

      a.    Exhibits:

            Exhibit number 31.1   Certification of Chief Executive Officer
                                  Pursuant To Rule 13a-14 of the Securities
                                  Exchange Act of 1934, As Adopted Pursuant To
                                  Section 302 of The Sarbanes-Oxley Act Of 2002.

            Exhibit number 31.2   Certification of Chief Financial Officer
                                  Pursuant To Rule 13a-14 of the Securities
                                  Exchange Act of 1934, As Adopted Pursuant To
                                  Section 302 of The Sarbanes-Oxley Act Of 2002.

             Exhibit number 32.1  Certification of Chief Executive Officer
                                  Pursuant To 18 U.S.C. Section 1350, As Adopted
                                  Pursuant To Section 906 Of The Sarbanes-Oxley
                                  Act Of 2002.

             Exhibit number 32.2  Certification of Chief Financial Officer
                                  Pursuant To 18 U.S.C. Section 1350, As Adopted
                                  Pursuant To Section 906 Of The Sarbanes-Oxley
                                  Act Of 2002.

      b.    Current Reports on Form 8-K:

              A Form 8-K was filed on May 18, 2004 reporting Item 7 and Item 12.


                                       15
<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                       SPEEDUS CORP.


Date: August 16, 2004                  By: /s/ Shant S. Hovnanian
                                           ----------------------
                                       Shant S. Hovnanian
                                       Chairman of the Board, President and
                                       Chief Executive Officer


Date: August 16, 2004                  By: /s/ Thomas M. Finn
                                           -------------------
                                       Thomas M. Finn
                                       Treasurer and Chief Financial Officer


                                       16